Contrasting Westaim (OTCMKTS:WEDXF) and Daxor (NASDAQ:DXR)

Daxor (NASDAQ:DXR) and Westaim (OTCMKTS:WEDXF) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, profitability, analyst recommendations and valuation.

Profitability

This table compares Daxor and Westaim’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Westaim	284.74%	7.76%	7.29%

Dividends

Daxor pays an annual dividend of $0.03 per share and has a dividend yield of 0.4%. Westaim pays an annual dividend of $0.09 per share and has a dividend yield of 0.4%. Westaim pays out 5.2% of its earnings in the form of a dividend.

Insider & Institutional Ownership

1.3% of Daxor shares are held by institutional investors. 59.0% of Daxor shares are held by company insiders. Comparatively, 4.2% of Westaim shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Daxor and Westaim, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	0	1	0	3.00
Westaim	0	0	0	0	0.00

Daxor currently has a consensus target price of $24.75, indicating a potential upside of 236.28%. Given Daxor’s stronger consensus rating and higher probable upside, research analysts plainly believe Daxor is more favorable than Westaim.

Volatility & Risk

Daxor has a beta of -0.46, meaning that its share price is 146% less volatile than the S&P 500. Comparatively, Westaim has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500.

Valuation & Earnings

This table compares Daxor and Westaim”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	$2.61 million	13.66	N/A	N/A	N/A
Westaim	$8.63 million	55.25	$183.98 million	$1.74	12.83

Westaim has higher revenue and earnings than Daxor.

Summary

Daxor beats Westaim on 7 of the 13 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

About Westaim

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.